3Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed verus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol, 2004,22(9) :1589 - 1597.
4Scaglioti G, Parikh P, yon Pawel J, et al. Phase III study comparing eisplatin plus gemeitatine with cisplatin plus pemetrexed in chemotherapy: naive patients with advanced-stage non-small cell lung cancer. J Clin Oncol,2008 ,26 :3543 - 3551.
5M. H. Cullen,P Zafloukal,S Sirenson ,et al. A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small- cell lung cancer. Annals of Oncol,2008, 19 (5) :939 - 945.
6Adjei A A. Clinical studies of pemetrexed and gemeitabine combinations. Ann Oncol,2006,17 ( suppl 5 ) : V29 - V32.
二级参考文献35
1[1]Calvert H. An overview of folate metabolism: Features relevant to the action and toxicities of antifolate anticancer agents. Semin Oncol, 1999, 26 (2 Suppl 6) :3
2[2]Sierra EE, Goldman ID. Recent advances in the understanding of the mechanism of membrane transport of folates and antifolates.Semin Oncol. 1999, 26 (2 Suppl 6): 11
3[3]Mendelsohn LG, Shih C, Chen VJ, et al. Enzyme inhibition,polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol, 1999, 26 (2 Suppl 6):42
4[4]Calvert H. MTA, a novel multitargeted antifolate, from preclinical to phase Ⅰ and beyond: Summary and conclusions. Semin Oncol, 1999, 26 (2 Suppl 6): 105
5[5]Schultz RM, Chen VJ, Bewley JR, et al. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Semin Oncol, 1999, 26 (2 Suppl 6) :68
6[6]Calvert AH, Walling JM. Clinical studies with MTA. Br J Cancer, 1998, 78 (Suppl 3) :35
7[7]Newell DR. Clinical pharmacokinetics of antitumor antifolates.Semin Oncol, 1999, 26 (2 Suppl 6):74
8[8]Thodtmann R, Depenbrock H, Dumez H, et al. Clinical and pharmacokinetic phase Ⅰ study of multitargeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol,1999, 17 (10):3009
9[9]Bajetta E, Celio L, Buzzoni R, et al. Phase Ⅱ study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer. Ann Oncol, 2003, 14(10): 1543
10[10]Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase Ⅲstudy of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol, 2003, 21 (14):2636
4Hanna N,Shepherd FA,Fossella FV,et al.Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy[J].J Clin Oncol,2004,22(9):1 589-1 597.
5Scaglioti G,Parikh P,Pawel J,et al.Phase Ⅲ study comparing cisplatin plus gemcitatine with cisplatin plus pemetrexed in chemo therapy-naive patients with advanced-stage non-small cell lung cancer[J].J Clin Oncol,2008,26(21):3 543-3 551.
6Brown T, Boland A, Bagust A,et al. Gefitinib for the first-linetreatment of locally advanced or metastatic non-small cell lung canc-er[ J]. Health Technol Assess, 2010,14(2) :71 -79.
7Nuijten MJ, Aultman R, Carpeno J, et al. An indirect comparisonof the efficacy of bevacizumab plus carboplatin and paclitaxel versuspemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non - small cell lung cancer[ J]. Cur-rent medical research and opinion, 2011 ,27(11) :2193 -2201.
8Bunn PA. Chemotherapy for advanced non-small-cell lung cancer who what when why[ J]. Clin Oncol,2002,20: 23-33.
9Shepherd F, Dancey J, Ramlan R, et al. Prospective randomized trim of doeetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy [J]. J Clin Oneol, 2000, 18: 2095-2103.
10Adjei A A. Pemetrexed (ALIMTA),a novel multitargeted antineo-plastic agent [J].Clin Cancer Res,2004,10 (12): 4276-4280.
